EC Gynaecology

Research Article Volume 12 Issue 3 - 2023

Recombinant LH in Ovarian Stimulation as a Personalized Medicine

Ben-Aicha Gonzalez Yasmina*

Consultant in Obstetrics and Gynaecology and Reproductive Medicine at University Government Hospital Marie Curie (ISPPC), Charleroi, Belgium

*Corresponding Author: Ben-Aicha Gonzalez Yasmina, Consultant in Obstetrics and Gynaecology and Reproductive Medicine at University Government Hospital Marie Curie (ISPPC), Charleroi, Belgium.
Received: January 24, 2023; Published: February 20, 2023

The number of babies born from assisted reproductive technology is increasing year by year. During this procedure some drugs are used to stimulate the ovaries. The combination of drugs and their dosing is known as a “protocol” which are designed to achieve maximum oocyte yields. Although the doses and rates are always a matter of debate.

Luteinizing hormone is essential for normal follicular development and oocyte maturation. Nevertheless, the use of this drug in an ovarian stimulation cycle has been widely discussed.

This review evaluates the effect of recombinant luteinizing hormone supplementation on ovarian stimulation and the outcomes in reproductive medicine the most recent studies.

Keywords: Assisted Reproduction Technologies; LH Supplementation; Ovarian Stimulation

  1. Adashi EY. “The ovarian follicular apparatus”. In: Adashi EY, Rock J, Rosenwaks Z, editions. Reproductive Endocrinology, Surgery, and Technology. Lippincott-Raven, Philadelphia (1996): 7-40.
  2. Dorrington JH and Armstrong DT. “Effects of FSH on gonadal function”. Recent Progress in Hormone Research 35 (1979): 301-342.
  3. Zeleznik AJ., et al. “Granulosa cell maturation in the rat: increased binding of human chorionic gonadotropin following treatment with follicle stimulating hormone in vivo”. Endocrinology 95 (1974): 818-825.
  4. Shima K., et al. “Gonadotropin binding sites in human ovarian follicles and corpora lutea during the menstrual cycle”. Obstetrics and Gynecology 69 (1987): 800-806.
  5. Hillier SG. “Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis”. Human Reproduction 9 (1994): 188-191.
  6. Zeleznik AJ and Hillier SG. “The role of gonadotropins in the selection of preovulatory follicle”. Clinical Obstetrics and Gynecology 27 (1984): 927-940.
  7. Hall JE., et al. “Hypothalamic gonadotropin-releasing hormone secretion and follicle stimulating hormone dynamics the luteal-follicular transition”. Journal of Clinical Endocrinology and Metabolism 74 (1992): 600-607.
  8. Filicori M., et al. “Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle”. Journal of Clinical Endocrinology and Metabolism 62 (1986): 1136-1144.
  9. Filicori M and Cognigni GE. “Roles and novel regimens of luteinizing hormone and follicle stimulating hormone in ovulation induction”. Journal of Clinical Endocrinology and Metabolism 86 (2001): 1437-1441.
  10. Campbell BK., et al. “Examination of the relative role of FSH and LH in the mechanism of ovulatory follicle selection in sheep”. Journal of Reproduction and Fertility 117 (1999): 355-367.
  11. Louvet JP., et al. “Evidence of a role of androgens in follicular maturation”. Endocrinology 97 (1975): 366-372.
  12. Filicori M., et al. “Different gonadotropin and leuprolin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis”. Fertility and Sterility 65 (1996): 387-393.
  13. Sills ES., et al. “A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization”. Human Reproduction 9 (1999): 2230-2235.
  14. Balasch J., et al. “The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction”. The Journal of Assisted Reproduction and Genetics 5 (2001): 250-256.
  15. Humaidan P., et al. “Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study”. Reproductive BioMedicine Online 6 (2004): 635-643.
  16. Sauer MV., et al. “Comparative efficacy and safety of cetrorelix with or without midcycle recombinant LH and leuprolide acetate for inhibition of LH surges in assisted reproduction”. Reproductive BioMedicine Online 5 (2004): 487-493.
  17. Griesinger G., et al. “Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol”. Human Reproduction 5 (2005): 1200-1206.
  18. Tarlatzis B., et al. “The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study”. Human Reproduction 1 (2006): 90-94.
  19. Fábregues F., et al. “Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age”. Fertility and Sterility 4 (2006): 925-931.
  20. Bart CJM Fauser. “Chapter 30 - Medical Approaches to Ovarian Stimulation for Infertility, Editor(s): Jerome F. Strauss, Robert L”. Barbieri, Yen and Jaffe's Reproductive Endocrinology (Eighth Edition), Elsevier (2019): 743-778.
  21. Bosch E., et al. “The impact of luteinizing hormone supplementation in gonadotropin releasing hormone antagonist cycles: an age-adjusted analysis”. Fertility and Sterility (2010).
  22. Drakopoulos P., et al. “Editorial: Recent Advances in Ovarian Stimulation”. Frontiers in Endocrinology 13 (2022): 874628.
  23. Elkin Muñoz., et al. “The Role of LH in Ovarian Stimulation”. Current Pharmaceutical Biotechnology 13 (2012): 409-416.
  24. Freis A., et al. “Endometrial expression of receptivity markers subject to ovulation induction agents”. Archives of Gynecology and Obstetrics 6 (2019): 1741-1750.
  25. Filicori M. “The role of luteinizing hormone in folliculogenesis and ovulation induction”. Fertility and Sterility 3 (1999): 405-414.
  26. Marchiani S., et al. “LH supplementation of ovarian stimulation protocols influences follicular fluid steroid composition contributing to the improvement of ovarian response in poor responder women”. Scientific Reports 1 (2020): 12907.
  27. Mochtar MH., et al. “Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles”. Cochrane Database of Systematic Reviews 2 (2007): CD005070.

Ben-Aicha Gonzalez Yasmina. Recombinant LH in Ovarian Stimulation as a Personalized Medicine. EC Gynaecology 12.3 (2023): 11-15.